Patents by Inventor ERIC JAMES GOWANS

ERIC JAMES GOWANS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240123051
    Abstract: The present disclosure relates to vaccines and methods for the prevention and treatment of Zika virus infection. Particularly, the present disclosure relates to viral and DNA vaccine vectors which includes or encode for secreted immunogenic peptides of NS1 that eliciting a protective immune response and prevent Zika virus infection of a subject.
    Type: Application
    Filed: June 13, 2023
    Publication date: April 18, 2024
    Applicant: THE UNIVERSITY OF ADELAIDE
    Inventors: Eric James Gowans, Branka Grubor-Bauk, Danushka Wijesundara
  • Patent number: 11738079
    Abstract: The present disclosure relates to vaccines and methods for the prevention and treatment of Zika virus infection. Particularly, the present disclosure relates to viral and DNA vaccine vectors which includes or encode for secreted immunogenic peptides of NS1 that eliciting a protective immune response and prevent Zika virus infection of a subject.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: August 29, 2023
    Inventors: Eric James Gowans, Branka Grubor-Bauk, Danushka Wijesundara
  • Publication number: 20210228704
    Abstract: The present disclosure relates to vaccines and methods for the prevention and treatment of Zika virus infection. Particularly, the present disclosure relates to viral and DNA vaccine vectors which includes or encode for secreted immunogenic peptides of NS1 that eliciting a protective immune response and prevent Zika virus infection of a subject.
    Type: Application
    Filed: July 23, 2019
    Publication date: July 29, 2021
    Applicant: THE UNIVERSITY OF ADELAIDE
    Inventors: Eric James Gowans, Branka Grubor-Bauk, Danushka Wijesundara
  • Patent number: 10052377
    Abstract: The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: August 21, 2018
    Assignee: ADELAIDE RESEARCH & INNOVATION PTY LTD
    Inventor: Eric James Gowans
  • Publication number: 20170106081
    Abstract: The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein.
    Type: Application
    Filed: January 3, 2017
    Publication date: April 20, 2017
    Inventor: Eric James Gowans
  • Patent number: 9585952
    Abstract: The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: March 7, 2017
    Assignee: ADELAIDE RESEARCH & INNOVATION PTY LTD
    Inventor: Eric James Gowans
  • Publication number: 20150216966
    Abstract: The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein.
    Type: Application
    Filed: May 16, 2013
    Publication date: August 6, 2015
    Applicant: ADELAIDE RESEARCH & INNOVATION Pty LTD
    Inventor: Eric James Gowans
  • Publication number: 20100143405
    Abstract: The present invention relates to a method of treating or preventing a virus infection in a subject. In particular, it relates to the use of autologous dendritic cells that have been matured and loaded ex vivo with hepatitis C virus (HCV) antigens, to initiate a cellular immune response in HCV-positive patients, after autologous transfusion.
    Type: Application
    Filed: August 25, 2005
    Publication date: June 10, 2010
    Inventors: David Charles Jackson, Lorena Elizabeth Brown, Lau Yuk Fai, Eric James Gowans
  • Publication number: 20090239265
    Abstract: An isolated polynucleotides comprising a HBsAg-S coding sequence that is adapted to receive an insert coding sequence, within a part of the HBsAg-S coding sequence that encodes an exposed site within the external loop of HBsAgS, and still encode a HBsAg-S that is able to assemble into a VLP. Proteins encoded by the polynucleotides, recombinant VLP's and various uses thereof are also described.
    Type: Application
    Filed: February 6, 2009
    Publication date: September 24, 2009
    Inventors: ERIC JAMES GOWANS, THOMAS BERNARD MACNAUGHTON, HANS JURGEN NETTER
  • Publication number: 20030211996
    Abstract: An isolated polyneucleotides comprising a HBsAg—S coding sequence that is adapted to receive an insert coding sequence, within a part of the HBsAg—S coding sequence that encodes an exposed site within the external loop of HBsAgS, and still encode a HBsAg—S that is able to assemble into a VLP. Proteins encoded by the polynucleotides, recombinant VLP's and various uses thereof are also described.
    Type: Application
    Filed: January 31, 2003
    Publication date: November 13, 2003
    Inventors: Eric James Gowans, Thomas Bernard MacNaughton, Hans Jurgen Netter